Bleeding‐related hospital admissions and 30‐day readmissions in patients with non‐valvular atrial fibrillation treated with dabigatran versus warfarin

Wallis C. Y. Lau; Xue Li; Ian Chi Kei Wong; Kenneth K. C. Man; Professor Gregory Lip; Wai K. Leung; Chung‐Wah Siu; Esther W. Chan

doi:10.1111/jth.13780

Back

Bleeding‐related hospital admissions and 30‐day readmissions in patients with non‐valvular atrial fibrillation treated with dabigatran versus warfarin

Article 2017 en

Related publications

Article2016

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Allison Keshishian, Shital Kamble, Xianying Pan, Jack Mardekian, Ruslan Horblyuk, Melissa Hamilton, Professor Gregory Lip

Article2016

Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

Iris Lin, Ruslan Horblyuk, Jack Mardekian, Sang Hee Park, Shital Kamble, Melissa Hamilton, Younos Abdulsattar, William Petkun, Joseph Menzin, Professor Gregory Lip

Article2021

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients

Steven Deitelzweig, Allison Keshishian, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Neeraja Balachander, Lisa Rosenblatt, Jack Mardekian, Jenny Jiang, Hüseyin Yüce, Professor Gregory Lip

Letter2020

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

Philippe Gabríel Steg, Grégory Ducrocq, Deepak L. Bhatt, Stefan H. Hohnloser, Matias Nordaby, Corinna Miede, Professor Gregory Lip, Jonas Oldgren, Jurriën M. ten Berg, Christopher P. Cannon

Article2018

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban

Ping G. Tepper, Jack Mardekian, Cristina Masseria, Hemant Phatak, Shital Kamble, Younos Abdulsattar, William Petkun, Professor Gregory Lip

Bleeding‐related hospital admissions and 30‐day readmissions in patients with non‐valvular atrial fibrillation treated with dabigatran versus warfarin

Discussion(0)

Related publications

Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients

Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban